(0.07%) 5 521.00 points
(0.12%) 39 890 points
(0.18%) 19 787 points
(0.01%) $81.64
(0.46%) $2.82
(-0.32%) $2 336.90
(-0.07%) $29.51
(0.27%) $1 004.50
(0.02%) $0.932
(0.05%) $10.54
(-0.01%) $0.788
(-0.56%) $87.50
-8.00% $ 0.881
Live Chart Being Loaded With Signals
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases...
Stats | |
---|---|
Dzisiejszy wolumen | 2.76M |
Średni wolumen | 634 418 |
Kapitalizacja rynkowa | 135.20M |
EPS | $-0.0582 ( Q3 | 2023-11-13 ) |
Następna data zysków | ( $0 ) 2024-08-15 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-3.04 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0960 (14.39%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-02 | Singer Michael | Buy | 178 000 | Common Stock |
2024-01-02 | Singer Michael | Buy | 228 000 | Stock Option (Right to Buy) |
2023-12-22 | Singer Michael | Sell | 3 000 | Series A Convertible Preferred Stock |
2024-01-02 | Davis Blaine | Buy | 3 110 000 | Employee Stock Option (right to buy) |
2024-01-02 | Davis Blaine | Buy | 2 424 000 | Common Stock |
INSIDER POWER |
---|
53.25 |
Last 97 transactions |
Buy: 26 530 299 | Sell: 8 848 103 |
Wolumen Korelacja
Selecta Biosciences Inc Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Selecta Biosciences Inc Korelacja - Waluta/Towar
Selecta Biosciences Inc Finanse
Annual | 2023 |
Przychody: | $0 |
Zysk brutto: | $0 (0.00 %) |
EPS: | $-0.00140 |
FY | 2023 |
Przychody: | $0 |
Zysk brutto: | $0 (0.00 %) |
EPS: | $-0.00140 |
FY | 2022 |
Przychody: | $110.78M |
Zysk brutto: | $38.40M (34.66 %) |
EPS: | $0.240 |
FY | 2021 |
Przychody: | $85.08M |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-0.220 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Selecta Biosciences Inc
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising SEL-313, a product candidate in preclinical stage to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to evaluate the appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and products for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat primary biliary cholangitis and other autoimmune diseases. The company has license and collaboration agreements with Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum; Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Ginkgo Bioworks Holdings, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej